# Integrated Analysis of Disulfidptosis-Related Genes Identifies CD2AP as a Potential Therapeutic Target for Hepatocellular Carcinoma

## TL;DR

This study identifies CD2AP as a potential biomarker and therapeutic target for hepatocellular carcinoma based on disulfidptosis-related genes.

## Contribution

The study introduces a new prognostic model for HCC using disulfidptosis-related genes and identifies CD2AP as a novel therapeutic target.

## Key findings

- A prognostic risk model using seven disulfidptosis-related genes was developed and validated for HCC prognosis.
- CD2AP was found to be highly expressed in HCC tissues and linked to disease severity.
- Down-regulation of CD2AP reduced HCC cell proliferation, migration, invasion, and EMT in vitro.

## Abstract

Hepatocellular carcinoma (HCC) is a deadly cancer with limited treatment options for patients at advanced stages. It is urgent to develop reliable prognostic risk models and identify more biomarkers to improve the clinical outcomes of patients with HCC. Disulfidptosis is a newly discovered form of regulated cell death (RCD), and research on the comprehensive roles of disulfidptosis-related genes (DRGs) in HCC prognosis and development remains limited. In this paper, we systematically analyzed the expression levels and prognostic profiles of 26 DRGs in HCC samples from The Cancer Genome Atlas (TCGA) cohort and developed a prognostic risk model using seven hub DRGs. The independent prognostic value of the risk model was further validated in the external cohort. The overall survival of patients with HCC in the low-risk group was significantly longer than that of those in the high-risk group. Subsequently, the protein level of CD2-associated protein (CD2AP) was found to be highly expressed in HCC clinical tissues and associated with the severity of HCC. In vitro experiments demonstrated that the down-regulation of CD2AP attenuated the proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) abilities of HCC cells. Taken together, our study revealed that the DRG CD2AP may serve as a potential biomarker for HCC and offer support for prognosis prediction of patients with HCC.